stockrow
Friday 6 November 2026
Export IMNN’s income statement to Excel — free account
Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00.
- EPS
- +74.9%
- Free cash flow
- −4.24%
Quarter to June 2026, against a year earlier
0.85
0.05
−5.56%
Follow IMNN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.44 | 1.15 | 1.90 | 1.25 | |
Current Ratio |
1.82 | 1.59 | 2.32 | 1.73 | |
Net Debt/EBITDA |
0.52 | 1.16 | 2.15 | 1.59 | |
Debt/Assets |
36.92% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
1.32 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.07 | 0.94 | 0.87 | 1.30 | |
Capex/Depreciation |
(0.33) | 0.00 | (0.02) | 0.00 | |
Interest Coverage |
(36.11) | — | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.58) | (0.79) | (1.72) | (1.51) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.59) | (0.79) | (1.72) | (1.51) | |
Cash per Share |
1.31 | 0.95 | 4.14 | 1.78 | |
Shareholders Equity per Share |
0.80 | 0.67 | 3.33 | 1.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.80 | 0.67 | 3.33 | 1.39 | |
Free Cash Flow |
(3.09) | (3.99) | (3.66) | (4.44) | |
Working Capital |
3.91 | 2.45 | 6.10 | 3.06 | |
Capital Expenditures |
(0.07) | — | 0.00 | 0.00 | |
Net Current Asset Value |
(2.11) | 1.96 | 5.50 | 2.35 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.68 | 1.41 | 1.35 | 1.74 | |
Average Assets |
11.89 | 7.44 | 11.00 | 11.69 | |
Average Common Equity |
2.30 | 1.91 | 5.65 | 6.14 |
Columns are period end dates · fundamentals updated 26 Oct 2026